MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
08. März 2023 17:36 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...